---
title: "PMV Pharmaceuticals Reports Increased Quarterly Loss"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265638324.md"
description: "PMV Pharmaceuticals, Inc. reported a Q3 net loss of $21.1 million, up from $19.2 million a year earlier. Operating expenses rose to $22.5 million due to increased research and development costs. Despite the losses, the company holds $129.3 million in cash and equivalents, ensuring operational continuity. PMV plans to advance its product candidates through clinical trials, with management confident in their strategic and financial position for ongoing R&D activities."
datetime: "2025-11-13T04:09:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265638324.md)
  - [en](https://longbridge.com/en/news/265638324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265638324.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265638324.md) | [English](https://longbridge.com/en/news/265638324.md)


# PMV Pharmaceuticals Reports Increased Quarterly Loss

Pmv Pharmaceuticals, Inc. ( (PMVP) ) has released its Q3 earnings. Here is a breakdown of the information Pmv Pharmaceuticals, Inc. presented to its investors.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, headquartered in Princeton, New Jersey. In its latest earnings report for the quarter ended September 30, 2025, PMV Pharmaceuticals reported a net loss of $21.1 million, compared to a net loss of $19.2 million in the same period last year. The company’s total operating expenses increased to $22.5 million, driven by higher research and development costs. Despite the losses, PMV Pharmaceuticals maintains a strong cash position with $129.3 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations. Looking ahead, PMV Pharmaceuticals plans to focus on advancing its product candidates through clinical trials, with the management expressing confidence in their strategic plans and financial position to support ongoing research and development activities.

### 相關股票

- [PMV Pharma (PMVP.US)](https://longbridge.com/zh-HK/quote/PMVP.US.md)

## 相關資訊與研究

- [These 3 ETFs Might Be Buy-the-Dip Candidates — But There's More to the Story](https://longbridge.com/zh-HK/news/281395458.md)
- [Realbotix to Deliver 19 AI Humanoid Robots as It Scales Production](https://longbridge.com/zh-HK/news/281387250.md)
- [Meet 'Dobby': The AI agent that could kill the app economy](https://longbridge.com/zh-HK/news/281354277.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/zh-HK/news/281311983.md)
- [SharonAI Secures Major Long-Term AI Cloud Services Deal](https://longbridge.com/zh-HK/news/281363534.md)